ADMA
ADMA
NASDAQ · Biotechnology

Adma Biologics Inc

$12.73
-0.48 (-3.63%)
As of Nov 7, 1:32 AM ET ·
Financial Highlights (FY 2026)
Revenue
484.18M
Net Income
139.43M
Gross Margin
57.4%
Profit Margin
28.8%
Rev Growth
+49.0%
D/E Ratio
0.15
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 57.4% 57.4% 49.6% 49.6%
Operating Margin 36.9% 33.2% -9.0% -9.9%
Profit Margin 28.8% 27.4% -10.4% -8.5%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 484.18M 324.86M 922.90M 1.03B
Gross Profit 277.87M 186.44M 457.58M 508.40M
Operating Income 178.52M 107.80M -82,955,088 -101,708,220
Net Income 139.43M 84.20M -95,808,796 -87,264,834
Gross Margin 57.4% 57.4% 49.6% 49.6%
Operating Margin 36.9% 33.2% -9.0% -9.9%
Profit Margin 28.8% 27.4% -10.4% -8.5%
Rev Growth +49.0% +49.0% +20.1% +10.2%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 194.20M 194.20M 1.56B 1.50B
Total Equity 1.29B 1.29B 2.42B 2.53B
D/E Ratio 0.15 0.15 0.64 0.59
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA 178.67M 113.89M -107,012,515 -125,992,506
Free Cash Flow — — -83,155,340 -96,884,239